Shock wave | Jotup

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, MODN, ABIO

Retrieved on:

Monday, April 8, 2024

ARCA, Model N, Shock wave, Sale, Aimco, Fraud, Johnson & Johnson, Vista Equity Partners, Advertising, Security (finance)

If you are a Shockwave shareholder, click here to learn more about your rights and options .

Key Points:

If you are a Shockwave shareholder, click here to learn more about your rights and options .
If you are an Apartment Income shareholder, click here to learn more about your rights and options .
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, KTRA, ABIO

Retrieved on:

Friday, April 5, 2024

Advertising, Shock wave, ARCA, Sale, Therapy, Fraud, Johnson & Johnson, Security (finance)

If you are a Shockwave shareholder, click here to learn more about your rights and options .

Key Points:

If you are a Shockwave shareholder, click here to learn more about your rights and options .
If you are a Kintara shareholder, click here to learn more about your rights and options .
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Enthusiast Gaming Advances Strategic Objectives with C$4.1 Million Sale of Select Non-Core Assets

Retrieved on:

Monday, April 1, 2024

Luminosity Gaming, Enthusiasm, Partnership, Pocket Gamer, Chairperson, Shock wave, Sale, EGLX, TSX, Asset, Interim, Luminosity, NFL, Enthusiast Gaming

LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming and media company, today announced it has entered into a definitive agreement (the “Asset Sale Agreement”) for the divestment of certain non-core and non-profitable casual gaming assets (the “Assets”) for a purchase price of approximately C$4.1 million.

Key Points:

LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming and media company, today announced it has entered into a definitive agreement (the “Asset Sale Agreement”) for the divestment of certain non-core and non-profitable casual gaming assets (the “Assets”) for a purchase price of approximately C$4.1 million.
The Assets comprise a subset of Enthusiast Gaming’s casual gaming business, and the divestment is a continuation of a number of recent strategic actions designed to enhance the Company’s operational efficiency while emphasizing high-margin revenue growth and sustainable profitability.
“We are swiftly executing on our strategic objectives including operational efficiency, enhancing liquidity, and building a platform of sustainable profitability,” said Adrian Montgomery, Board Chair and Interim CEO of Enthusiast Gaming.
“This sale of a subset of non-core and non-profitable assets for C$4.1 million underscores our dedication to strengthening our balance sheet while simultaneously reducing operating costs.

Shockwave Medical to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on:

Wednesday, December 20, 2023

Interest, Conference, Shock wave

SANTA CLARA, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, which is being held from Monday, January 8 to Thursday, January 11, 2024, in San Francisco, CA.

Key Points:

SANTA CLARA, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, which is being held from Monday, January 8 to Thursday, January 11, 2024, in San Francisco, CA.
Shockwave management is scheduled for a live presentation on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Time.
Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at: https://ir.shockwavemedical.com .

Shockwave Medical to Participate in the Piper Sandler 35th Annual Healthcare Conference

Retrieved on:

Wednesday, November 15, 2023

Interest, Conference, Piper Sandler Companies, Shock wave, Pharmaceutical industry

SANTA CLARA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper Sandler 35th Annual Healthcare Conference, which is being held from Tuesday, November 28 to Thursday, November 30, 2023 in New York, NY.

Key Points:

SANTA CLARA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper Sandler 35th Annual Healthcare Conference, which is being held from Tuesday, November 28 to Thursday, November 30, 2023 in New York, NY.
Shockwave management is scheduled for a live fireside chat on Wednesday, November 29, 2023, at 1:30 p.m. Eastern Time.
Interested parties may access a live and archived webcast of the event on the "Investors" section of the company’s website at: https://ir.shockwavemedical.com .

Enthusiast Gaming Reports Third Quarter 2023 Financial Results

Retrieved on:

Monday, November 13, 2023

“We are making solid progress against our strategy to build the most scaled gaming communities in North America -- and a platform for significant growth,” commented Nick Brien, Chief Executive Officer. “Our efforts include sweeping changes across nearly every facet of the organization that are positioning the company for growth, profitability and value creation. As a measure of our progress, in the quarter we booked our largest branded solutions sale to date. We continue to expect to be profitable in the fourth quarter, entering next year as a self-sustaining business as we shift from a year of transformation velocity in 2023 to a year of growth velocity in 2024.”

Key Points:

LOS ANGELES, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming media and entertainment company, today announced financial results for the three and nine months ended September 30, 2023 (“Q3 2023”).
The results represent 28% year-over-year growth in Unique Visitor traffic to Enthusiast Gaming’s digital media Property of gaming communities, content, and creators (Comscore Media Metrix® Multi-Platform, Total Audience, September 2023, U.S.).
Results in Q3 2023 and Q3 2022 included a non-cash impairment expense of $51.7 million and $31.3 million respectively.
Conference call details:
A replay of the webcast will be available on the Investor page of the Enthusiast Gaming website at enthusiastgaming.com/investors.

The Best Class 4 Laser Therapy Machine Takes Center Stage at The 55th Dusseldorf International Hospital and Medical Equipment Exhibition in 2023

Retrieved on:

Thursday, November 30, 2023

Attention, Safety, Shock wave, Human, Multimedia, Medicine, Subcutaneous tissue, LLLT, Exhibition, Laser, Christmas

This innovative showcase includes Smart/Smart Ice laser therapy system, PowerCure/PowerCure Pro handheld home laser device, and SWAVE-200 electromagnetic shock wave therapeutic apparatus.

Key Points:

This innovative showcase includes Smart/Smart Ice laser therapy system, PowerCure/PowerCure Pro handheld home laser device, and SWAVE-200 electromagnetic shock wave therapeutic apparatus.
In the realm of pain relief, the Smart/Smart Ice laser therapy system caters to the diverse needs of those enduring discomfort.
The top-selling Smart Ice Laser Therapy System was widely embraced at this medical expo.
At the exhibition, the PowerCure/PowerCure Pro handheld laser device stands out as a preferred Low-level Laser Therapy (LLLT) solution.

iQIYI Joins Forces with Leading Film Distributors in Malaysia and Singapore to Release Chinese Films

Retrieved on:

Monday, November 27, 2023

BEIJING, Nov. 27, 2023 /PRNewswire/ -- On November 27, iQIYI, an innovative market-leading online entertainment service in China, announced the partnerships with GSC Movies in Malaysia and Clover Films in Singapore. These collaborations aim to expand iQIYI's selection of premium Chinese films available to global viewers and leverage the extensive film distribution networks and rich experience of GSC Movies and Clover Films.

Key Points:

These collaborations aim to expand iQIYI's selection of premium Chinese films available to global viewers and leverage the extensive film distribution networks and rich experience of GSC Movies and Clover Films.
"By partnering with GSC Movies and Clover Films for theatrical distribution, we can seamlessly bring Chinese-language films to audiences in Singapore and Malaysia through effective resource integration.
GSC Movies is the largest independent film distributor in Malaysia, offers a diverse range of content including Chinese films, Japanese anime, other Asian films, and independent English-language films.
Clover Films, a leading film company in Singapore, has made significant contributions to the local film landscape since its inception.

Shockwave Medical Reports Third Quarter 2023 Financial Results

Retrieved on:

Monday, November 6, 2023

Medicare, Physician, RVU protocol, EBITDA, PFS, Shock wave, IVL, United, Remuneration, Centers for Medicare & Medicaid Services, Growth, Investment, Patient, CMS, Cardiovascular disease, Video game, Pharmaceutical industry

SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended September 30, 2023.

Key Points:

SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended September 30, 2023.
Gross profit for the third quarter of 2023 was $161.5 million compared to $113.5 million for the third quarter of 2022.
Total operating expenses for the third quarter of 2023 were $117.9 million, a 54% increase from $76.7 million in the third quarter of 2022.
Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Monday, November 6, 2023, to discuss its third quarter 2023 financial results.

Shockwave Medical Introduces Enhanced Coronary IVL Catheter in the United States

Retrieved on:

Friday, October 20, 2023

Food, C2, MD, Shock wave, IVL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Level 2, St. Francis Hospital, Workflow, TCT, Calcium, Cardiovascular disease, Medical imaging

SANTA CLARA, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the planned U.S. introduction of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter following approval by the U.S. Food and Drug Administration. The Shockwave C2+ catheter provides 50 percent more pulses per catheter than the Shockwave C2 catheter that was approved in the U.S. in 2021. The enhanced C2+ catheter will make its U.S. debut at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation, with the full commercial launch planned for the beginning of November.

Key Points:

SANTA CLARA, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the planned U.S. introduction of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter following approval by the U.S. Food and Drug Administration.
The Shockwave C2+ catheter provides 50 percent more pulses per catheter than the Shockwave C2 catheter that was approved in the U.S. in 2021.
The enhanced C2+ catheter will make its U.S. debut at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation, with the full commercial launch planned for the beginning of November.
“The enhancements of Shockwave C2+ will be an added benefit of IVL for optimally treating complex calcium, including more diffuse disease, as well as nodular and thick, eccentric calcium,” said Richard Shlofmitz, MD, Chairman, Department of Cardiology, St. Francis Hospital in Roslyn, New York, who performed the first U.S. commercial case with Shockwave C2+.